On August 10, Core Scientific, Inc. declined 5.05% in regular trading, trading at $19.935 per share, with turnover of approximately $73.85 million.

The decline reflects continued pressure from the company's Q2 earnings report, which showed a net loss of $3.32 per diluted share — far exceeding analyst consensus estimates of a $0.06 to $0.10 loss. Revenue for the quarter reached $164.2 million, surpassing the expected $143-145 million, but the magnitude of losses overshadowed the top-line beat. The loss widened dramatically from $0.04 per share in the year-ago period.

Adding to bearish sentiment, the company's recently announced partnership with AMD — providing up to 2.5 gigawatts of data center capacity — includes market-priced warrants allowing AMD to purchase Core Scientific common stock, raising dilution concerns among investors. While B. Riley raised its price target to $42 and Keefe Bruyette upgraded the stock to Outperform, near-term selling pressure from the outsized loss and equity dilution risk continues to dominate trading.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)